Shredding (disassembling genomic data)

Frost & Sullivan Honors Komodo Health with Technology Innovation Leadership Award for Its Data-Driven Platform to Improve Patient Care

Retrieved on: 
Thursday, November 2, 2023
Komodo, Sentinel, RWD, Frost, Health care, Health, Health information management, Shredding (disassembling genomic data), Algorithm, Entrepreneurship, RWE, Research, Enterprise, Genomics, Disease, EHR, Cause of action, Patient, Diagnosis, Pulse, SAN, Software as a service, Medical device, Pharmaceutical industry, Sales, Aperture

SAN ANTONIO and SAN FRANCISCO, Nov. 2, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the real-world evidence (RWE) IT solutions industry and, based on its findings, recognizes Komodo Health with the 2023 North American Technology Innovation Leadership Award. Komodo is an American software-as-a-service (SaaS) provider that converts vast amounts of data into meaningful insights to increase productivity and deliver exceptional value to its healthcare customers.

Key Points: 
  • Moreover, Komodo's solutions are fully scalable and customizable and can integrate seamlessly with today's technology and business tools.
  • "Essentially, it offers a seamless way for clients to integrate their IT systems with its platform without a rip-and-replace approach.
  • Thus, Komodo prioritizes providing a scalable and efficient platform that delivers customer satisfaction by leveraging technology and providing thought partnerships where necessary," said Ojaswi Rana, Best Practices Research Analyst at Frost & Sullivan.
  • Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development.

Frost & Sullivan Honors Komodo Health with Technology Innovation Leadership Award for Its Data-Driven Platform to Improve Patient Care

Retrieved on: 
Thursday, November 2, 2023
Komodo, Sentinel, RWD, Frost, Health care, Health, Health information management, Shredding (disassembling genomic data), Algorithm, Entrepreneurship, RWE, Research, Enterprise, Genomics, Disease, EHR, Cause of action, Patient, Diagnosis, Pulse, SAN, Software as a service, Medical device, Pharmaceutical industry, Sales, Aperture

SAN ANTONIO and SAN FRANCISCO, Nov. 2, 2023 /PRNewswire/ -- Frost & Sullivan recently researched the real-world evidence (RWE) IT solutions industry and, based on its findings, recognizes Komodo Health with the 2023 North American Technology Innovation Leadership Award. Komodo is an American software-as-a-service (SaaS) provider that converts vast amounts of data into meaningful insights to increase productivity and deliver exceptional value to its healthcare customers.

Key Points: 
  • Moreover, Komodo's solutions are fully scalable and customizable and can integrate seamlessly with today's technology and business tools.
  • "Essentially, it offers a seamless way for clients to integrate their IT systems with its platform without a rip-and-replace approach.
  • Thus, Komodo prioritizes providing a scalable and efficient platform that delivers customer satisfaction by leveraging technology and providing thought partnerships where necessary," said Ojaswi Rana, Best Practices Research Analyst at Frost & Sullivan.
  • Frost & Sullivan Best Practices Awards recognize companies in various regional and global markets for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development.

GeneDx to Participate in World Orphan Drug Congress Keynote and Panel Presentations

Retrieved on: 
Tuesday, May 23, 2023
Partnership, Drug development, GeneDx, Research, WWOX, CHD2, Exome, Congress, Strategic partnership, Best practice, Patient, Data, Inclusive, Diversity, WGS, Shredding (disassembling genomic data), Ecosystem, Therapy, IND, Pharmaceutical industry

STAMFORD, Conn., May 23, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it will participate in multiple presentations at the World Orphan Drug Congress in Washington, D.C., May 23-25, 2023.

Key Points: 
  • STAMFORD, Conn., May 23, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it will participate in multiple presentations at the World Orphan Drug Congress in Washington, D.C., May 23-25, 2023.
  • The keynote session will highlight how GeneDx’s deeply curated, 20 plus year genomic dataset combined with strong research and development experience of a biopharma partner accelerates drug development programs.
  • The panel will discuss how the company’s partnership with Mahzi Therapeutics has helped advance IND-enabling activities and clinical development for the company’s WWOX and CHD2-related drug candidates.
  • To learn more about partnering with GeneDx for biopharmaceutical, academic research, and patient advocacy collaborations, please visit www.genedx.com/collaborators .

Komprise Automates Unstructured Data Discovery with Smart Data Workflows

Retrieved on: 
Thursday, May 19, 2022
API, AI, IOT, Information technology, Crash, GDPR, Abraxis BioScience, Industry, Time, Compliance, Mutation, Shredding (disassembling genomic data), Genomics, Machine learning, CEO, Data management, GLOBE, Medical device, Computer data storage, Feed manufacturing

CAMPBELL, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Komprise , the leader in analytics-driven unstructured data management and mobility, today announced Komprise Smart Data Workflows, a systematic process to discover relevant file and object data across cloud, edge and on-premises datacenters and feed data in native format to AI and machine learning (ML) tools and data lakes.

Key Points: 
  • CAMPBELL, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Komprise , the leader in analytics-driven unstructured data management and mobility, today announced Komprise Smart Data Workflows, a systematic process to discover relevant file and object data across cloud, edge and on-premises datacenters and feed data in native format to AI and machine learning (ML) tools and data lakes.
  • This creates an unstructured data blind spot, resulting in billions of dollars in missed big data opportunities.
  • Komprise Global File Index and Smart Data Workflows together reduce the time it takes to find, enrich and move the right unstructured data by up to 80%.
  • Whether its massive volumes of genomics data, surveillance data, IoT, GDPR or user shares across the enterprise, Komprise Smart Data Workflows orchestrate the information lifecycle of this data in the cloud to efficiently find, enrich and move the data you need for analytics projects, says Kumar Goswami, CEO of Komprise.

OpGen subsidiary Ares Genetics announces the strategic expansion of ARESdb proprietary contents

Retrieved on: 
Tuesday, December 14, 2021
Sequence, Database, Hospital, Solution, Antimicrobial resistance, U.S. Securities and Exchange Commission, Infection, NGS, Nadine Opgen-Rhein, Securities Exchange Act of 1934, Personal Data Privacy and Security Act of 2009, P, Growth, Genome, Public health, Genetics, Private Securities Litigation Reform Act, Nasdaq, AST, COVID-19, Securities Act of 1933, Ares, Adoption, Microbiology, CEO, Goal, Artificial intelligence, Machine learning, Shredding (disassembling genomic data), INT, Security (finance), Marker beacon, AMR, Whole genome sequencing, Use, GLOBE, Informatics, Analysis, Precision medicine, Technology, Phase II, Fine chemical, Pharmaceutical industry, Antibiotics, MD, Reg Rattey

During Phase 2, Ares will gain access to 1,000 proprietary genome and AST datasets thereby strategically enriching ARESdb with proprietary data for key pathogens.

Key Points: 
  • During Phase 2, Ares will gain access to 1,000 proprietary genome and AST datasets thereby strategically enriching ARESdb with proprietary data for key pathogens.
  • ARESdb is central to our development of AI-powered applications for AMR prediction stated Dr.Arne Materna, CEO of Ares Genetics.
  • Ares Genetics intends to further increase the value of ARESdb and grow its contents in the coming months and years through strategic collaborations with external partners and by supporting clinical trials conducted by its affiliates at OpGen.
  • This press release includes statements regarding Ares Genetics strategic expansion of ARESdb and certain of its related collaboration arrangements.

Bionano Genomics Reports Third Quarter 2021 Financial Results and Highlights Recent Business Progress

Retrieved on: 
Thursday, November 4, 2021
The Journal of Molecular Diagnostics, Lymphatic system, Commercial, European Society for Medical Oncology, Amniocentesis, OGM, Genomics, Development, Leadership, FSHD, SAN, CVS, General manager, NASDAQ, Hospital, Doctor of Philosophy, NGS, Growth, Investment, Cytogenetics, Lloyds Bank Corporate Markets, European Society of Human Genetics, Lists of publishing companies, Software, Academic health science centre, Molecular diagnostics, Acquisition, GLOBE, Research and development, Company, Genome, Solution, Constitution, Facioscapulohumeral muscular dystrophy, Journal, Human genetics, BDA, Reproductive health, Shredding (disassembling genomic data), DNA, Patient, Total, Cryptocurrency, Management, Pharmaceutical industry, Medical imaging, Lithium

for microarray and next-generation sequencing (NGS), we are transitioning Bionano Genomics from being the structural variation company into a data solutions provider.

Key Points: 
  • for microarray and next-generation sequencing (NGS), we are transitioning Bionano Genomics from being the structural variation company into a data solutions provider.
  • Chris Stewart, Chief Financial Officer of Bionano added: Q3 was another excellent quarter.
  • Gross margin for the third quarter of 2021 was 24.8%, compared to 37.3% in the prior quarter and 33.4% from the third quarter of 2020.
  • The increase in cash is primarily due to the equity raises that were completed in the first quarter of 2021.

OpGen Subsidiary Ares Genetics Launches AREScloud

Retrieved on: 
Thursday, October 21, 2021
Shredding (disassembling genomic data), Genotype, Technology, Securities Act of 1933, PCR, Hospital, Genome, Goal, Informatics, Genomics, Lighthouse, WGS, NGS, Genetics, Infection, Security (finance), U.S. Securities and Exchange Commission, Adoption, Private Securities Litigation Reform Act, World Health Organization, Epidemiology, Policy, World, Virulence, Oxford Nanopore Technologies, IPC, Precision medicine, Software, CEO, COVID-19, Microbiology, Laboratory, AMR, Nadine Opgen-Rhein, WHO, Solution, Health, Nasdaq, Personal Data Privacy and Security Act of 2009, GLOBE, Securities Exchange Act of 1934, Plasmid, Whole genome sequencing, AI, Vaccine

(Nasdaq: OPGN, OpGen), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that its subsidiary Ares Genetics , which strives to become a leader in bacterial genomics and the AI-powered prediction of antimicrobial resistance (AMR), has commercially launched its AREScloud web application.

Key Points: 
  • (Nasdaq: OPGN, OpGen), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that its subsidiary Ares Genetics , which strives to become a leader in bacterial genomics and the AI-powered prediction of antimicrobial resistance (AMR), has commercially launched its AREScloud web application.
  • The performance of AREScloud bioinformatics pipelines for isolate WGS has been validated in several clinical studies.
  • OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease.
  • This press release includes statements regarding the commercial launch of AREScloud, a web application aimed at accelerating the analysis of sequenced clinical isolates.